Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 375
Two Years into the COVID-19 Pandemic: Lessons Learned
Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 9, pp. 1758-1814
Open Access | Times Cited: 103
Fitness effects of mutations to SARS-CoV-2 proteins
Jesse D. Bloom, Richard A. Neher
Virus Evolution (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 69
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
Judith M. White, Joshua T. Schiffer, Rachel Bender Ignacio, et al.
mBio (2021) Vol. 12, Iss. 6
Open Access | Times Cited: 57
Fitness effects of mutations to SARS-CoV-2 proteins
Jesse D. Bloom, Richard A. Neher
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 31
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
Federico Baldi, Chiara Dentone, Małgorzata Mikulska, et al.
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 29
Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic
Luis Daniel González-Vázquez, Miguel Arenas
Genes (2023) Vol. 14, Iss. 2, pp. 407-407
Open Access | Times Cited: 27
The Role of Cyclodextrins in COVID-19 Therapy—A Literature Review
Beatriz C. Almeida, Cátia Domingues, Filipa Mascarenhas‐Melo, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2974-2974
Open Access | Times Cited: 22
Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19
Xixi Jing, Min Xu, Deye Song, et al.
Immunity & Ageing (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 35
Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors
Bin Tan, M. Sacco, Haozhou Tan, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115667-115667
Open Access | Times Cited: 19
Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey
Shijie Qin, Yanhua Li, Likui Wang, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 17
Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells
Vanessa F. Merino, Yu Yan, Alvaro A. Ordoñez, et al.
Antiviral Research (2023) Vol. 211, pp. 105550-105550
Open Access | Times Cited: 15
Oral antivirals for the prevention and treatment of SARS-CoV-2 infection
Vincent Soriano, Carmen de Mendoza, Benson Edagwa, et al.
Aids Reviews (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 23
Quinones as Promising Compounds against Respiratory Viruses: A Review
Iván Chan‐Zapata, Rocı́o Borges-Argáez, Guadalupe Ayora‐Talavera
Molecules (2023) Vol. 28, Iss. 4, pp. 1981-1981
Open Access | Times Cited: 13
Structure-based design of SARS-CoV-2 papain-like protease inhibitors
Prakash D. Jadhav, Bo Huang, J. Osipiuk, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 116011-116011
Open Access | Times Cited: 13
Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models
Hong‐Yi Zheng, Tian‐Zhang Song, Yong‐Tang Zheng
动物学研究 (2024) Vol. 45, Iss. 4, pp. 747-766
Open Access | Times Cited: 4
Systematic Studies on the Anti-SARS-CoV-2 Mechanisms of Tea Polyphenol-Related Natural Products
Chenwei Li, Tai‐Ling Chao, Chin-Lan Lai, et al.
ACS Omega (2024) Vol. 9, Iss. 22, pp. 23984-23997
Open Access | Times Cited: 4
Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy
Weili Yang, Qi Li, Jing Sun, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 2442-2454
Open Access | Times Cited: 20
Polymodal Control of TMEM16x Channels and Scramblases
Emilio Agostinelli, Paolo Tammaro
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1580-1580
Open Access | Times Cited: 18
Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant
Cosimo Cianfarini, Luise Hassler, Jan Wysocki, et al.
Cells (2024) Vol. 13, Iss. 3, pp. 203-203
Open Access | Times Cited: 3
Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract
Tianyang Mao, Joo‐Young Kim, Mario A. Peña-Hernández, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 18
Open Access | Times Cited: 3
Rapid screening of SARS-CoV-2 variants, a key tool for pandemic surveillance
Irene Muñoz‐Gallego, María Ángeles Meléndez Carmona, Carmen Martín Higuera, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Vitamin D Levels as a Marker of Severe SARS-CoV-2 Infection
Lambros Athanassiou, Ifigenia Kostoglou‐Athanassiou, Sofia Nikolakopoulou, et al.
Life (2024) Vol. 14, Iss. 2, pp. 210-210
Open Access | Times Cited: 2
The SARS-CoV-2 Mpro Dimer-Based Screening System: A Synthetic Biology Tool for Identifying Compounds with Dimerization Inhibitory Potential
Ernawati Arifin Giri-Rachman, Vergio V. Effendy, Muhammad Hamzah Syaifullah Azmi, et al.
ACS Synthetic Biology (2024) Vol. 13, Iss. 2, pp. 509-520
Open Access | Times Cited: 2
Pathogenesis of COVID19 and the applications of US FDA-approved repurposed antiviral drugs to combat SARS-CoV-2 in Saudi Arabia: A recent update by review of literature
Almonther Abdullah Hershan
Saudi Journal of Biological Sciences (2024) Vol. 31, Iss. 7, pp. 104023-104023
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top